1. Statin Therapy in Patients With Insulin Resistance

2. Overview: Dr Bays

3. Risk of Developing NODM Meta-Analysis of Placebo-Controlled Statin Trials

4. Effect of Statins on Hepatic Fat and Insulin Sensitivity

5. Risk Factors That Increase Risk of Statin-Promoted Abnormalities in Glucose Metabolism

6. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

7. Assessment of Insulin Sensitivity

8. Clamp: Gold Standard for Measuring Insulin Sensitivity and Liver Fat

9. Euglycemic Hyperinsulinemic Clamp Trial Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

10. How Can We Measure Hepatic Insulin Sensitivity in Vivo?

11. How Can We Measure Hepatic Insulin Sensitivity in Vivo? (cont)

12. How Can We Measure Peripheral Insulin Sensitivity in Vivo?

13. How Can We Measure Hepatic Steatosis?

14. Patient Selection

15. Baseline Characteristics

16. Pitavastatin Has Neutral Effect on FBG Across Dose Range – Meta-Analysis of Patients With and Without Diabetes

17. Results: Liver Fat

18. Overall Results of Clamp Study

19. Patient Reassurance and Study Take-Away

20. It Takes a Team

21. Conclusion

22. Abbreviations

23. Abbreviations (cont)